Rachel H. Kravitz

Chief Tech/Sci/R&D Officer at NeoClone Biotechnology International LLC

Consumer Services

Health Technology

Profile

Rachel H.
Kravitz is currently working as a Research Director at NeoClone Biotechnology International LLC since 2003.
She completed her undergraduate degree from Tufts University in 1989 and received her doctorate degree from the University of California, Davis in 1998.

Rachel H. Kravitz active positions

Companies	Position	Start
NeoClone Biotechnology International LLC NeoClone Biotechnology International LLC BiotechnologyHealth Technology NeoClone Biotechnology International LLC engages in the production and supply of monoclonal antibody products. The firm offers antibodies to bacterial transcription proteins, RNA polymerase II, bacterial toxins, eukaryotic transcription proteins, neural proteins, cancer proteins, cardiac biomarkers, and interferon gamma, as well as offers cancer antibodies and Softag products. It provides contract monoclonal antibodies for companies and individual researchers, as well as for university and industry researchers. The company was founded in 1999 by Mark Jackson, Donal Kaehler, David Largaspaeda and Deven McGlenn and is headquartered in Madison, WI.	Chief Tech/Sci/R&D Officer	2002-12-31

All active positions of Rachel H. Kravitz

Training of Rachel H. Kravitz

Tufts University	Undergraduate Degree
University of California, Davis	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Rachel H. Kravitz's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
NeoClone Biotechnology International LLC NeoClone Biotechnology International LLC BiotechnologyHealth Technology NeoClone Biotechnology International LLC engages in the production and supply of monoclonal antibody products. The firm offers antibodies to bacterial transcription proteins, RNA polymerase II, bacterial toxins, eukaryotic transcription proteins, neural proteins, cancer proteins, cardiac biomarkers, and interferon gamma, as well as offers cancer antibodies and Softag products. It provides contract monoclonal antibodies for companies and individual researchers, as well as for university and industry researchers. The company was founded in 1999 by Mark Jackson, Donal Kaehler, David Largaspaeda and Deven McGlenn and is headquartered in Madison, WI.	Health Technology